Pharmaceutical Companies– tag –

In July 2025, the FDA began publishing past Complete Response Letters (CRLs). Triangulating those releases with company disclosures and primary reporting shows two dominant themes: CMC (quality/manufacturing/testing) & Pre-License In...

In this final volume, we summarize the latest developments in bispecific antibody drug R&D by leading biotech and pharma companies, as well as major approvals over the past year in the US and EU. We also highlight key trends and nota...

On August 6, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals), a protease activator, for adult and pediatric patients (≥1 year) with progressive H3 K27M-mutant...

Fierce Biotech's "Layoff Tracker 2025" has captured a wave of downsizing across the U.S. biotech landscape in the first half of 2025. This article breaks down key layoffs, underlying causes, industry categories impacted, and what this mi...

Introduction Over the past decade, major Japanese pharmaceutical companies have undergone significant evolution amidst global competition. Daiichi Sankyo, Takeda, Otsuka, and Astellas have each leveraged their strengths to enhance compet...

Introduction Between 2015 and 2025, global pharmaceutical giants have expanded into innovative therapeutic areas and pursued internalization or adoption of novel technologies. Based on the strategic movements of 22 companies, this articl...

A study published in the June 2025 issue of Cancer Discovery reports a novel small-molecule strategy to restore the tumor suppressor function of mutant p53 proteins. This work was also featured in a companion Perspective article, highlig...

Strategic Review: Investing in Marketed Products and Next-Gen Modalities Astellas Pharma has executed a series of acquisitions and collaborations from 2015 to 2025 focused on immuno-oncology, ophthalmology, neurology, and gene therapy. K...

Strategic Overview: Otsuka’s Global Expansion in CNS and Rare Diseases Otsuka Pharmaceutical has focused heavily on the central nervous system (CNS), leveraging U.S.-centered M&A and partnerships to expand its product pipeline. In re...

Strategic Review: Global Expansion through ADC-Focused Oncology Partnerships Daiichi Sankyo has built a strong global presence through its antibody-drug conjugate (ADC) platform. While previous partnerships with AstraZeneca and Seagen we...

Strategic Review: From Cystic Fibrosis to Gene Editing and Regenerative Medicine Vertex Pharmaceuticals has leveraged its dominance in cystic fibrosis (CF) treatment to expand into gene editing, regenerative medicine, pain management, an...

Strategic Review: Antibody Innovation Meets Gene Editing and RNA Technology Regeneron Pharmaceuticals has leveraged its VelociSuite antibody platform to become a leader in ophthalmology, oncology, and immunology. Over the last decade, it...

Strategic Overview: Expanding from Diabetes to Obesity, RNA, and Cardiometabolic Disease Novo Nordisk, known for its leadership in GLP-1 receptor agonists (Ozempic, Wegovy), has expanded significantly over the past decade. Through acquis...

Strategic Review: Shifting from Antivirals to Oncology and Cell Therapy Gilead Sciences, once dominant in the antiviral space—particularly in HIV and hepatitis C—has been facing declining revenue due to patent cliffs. Since 2015, the com...

Strategic Review: Building a Cell and Gene Therapy Pipeline with BlueRock and AskBio Over the past decade, Bayer has transitioned from conventional pharmaceuticals into emerging modalities like gene editing, cell therapies, and regenerat...

Strategic Review: Diversifying into Oncology and Immunology Through Innovative Partnerships Boehringer Ingelheim (BI), traditionally strong in cardiovascular and respiratory areas, has pivoted towards oncology and immune diseases over th...

A study published in the June 2025 issue of Cancer Discovery reveals how cancer-associated fibroblasts (CAFs) promote metastatic progression in breast cancer by suppressing natural killer (NK) cell cytotoxicity. This work was selected fo...

Strategic Review: From Biologics to Rare Diseases, Oncology, and RNA Innovation Over the past decade, Amgen has expanded beyond its legacy focus on bone and inflammatory diseases to invest heavily in oncology, RNA therapies, and rare dis...

Key Pharma Moves: Sanofi’s Acquisitions and Collaborations in Q1–Q3 2025 In 2025, Sanofi has executed several key strategic acquisitions and licensing deals focused on immunology, neurology, and rare diseases. Here's a summary of these d...

A study published online in June 2025 in Cancer Discovery reveals that **T-cell–dependent tumor regression** is a key mechanism underlying the efficacy of KRAS G12D inhibitors in pancreatic ductal adenocarcinoma (PDAC). KRAS G12D is a ma...